Bioventus (BVS) reported $568M in revenue for fiscal 2025, −0.9% year on year. That ranks #2132 by revenue among 2853 SEC filers and #206 in Healthcare. Net income was $22.7M, a net margin of 4.0%. Revenue has grown 8.9% a year on average since 2019 ($340M then). The fiscal 2025 balance sheet shows $684M in total assets, $51.2M in cash and $279M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $568M | −0.9% | FY20252025-12-31 |
| Gross profitGrossProfit | $388M | −0.0% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | $54.0M | +$69.2M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $22.7M | +$58.9M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $74.7M | +92.5% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $2.6M | +154.7% | FY20252025-12-31 |
| Total assetsAssets | $684M | −6.1% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $184M | +24.4% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $51.2M | +23.2% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $279M | −9.5% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-28 | $132M | $3.1M | Open → |
| Q2 20262026-06-27 | $153M | $33.4M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Bioventus Inc.
- Ticker
- BVS
- Exchange
- Nasdaq
- SIC classification
- Surgical & Medical Instruments & Apparatus (3841)
- Fiscal year end
- 12-31
- CIK
- 0001665988
Filings
- 10-QAug 5, 2026Open filing →
- 10-QMay 6, 2026Open filing →
- 10-KMar 5, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Ufp TechnologiesUFPT | $603M | $68.3M |
| Catalyst PharmaceuticalsCPRX | $589M | $214M |
| AlvotechALVO | $586M | $27.9M |
| BioventusBVS | $568M | $22.7M |
| Organogenesis HoldingsORGO | $564M | $37.0M |
| HUTCHMED (China)HCM | $549M | $457M |
| AtricureATRC | $535M | −$11.4M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Bioventus — Key figures |url=https://companiesranked.com/en/company/bioventus |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Bioventus — Key figures. CompaniesRanked. https://companiesranked.com/en/company/bioventusBibTeX
@misc{companiesranked-en-company-bioventus-2026,
author = {{CompaniesRanked}},
title = {{Bioventus — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/bioventus}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001665988-26-000011 · March 5, 2026
{{cite web |title=Bioventus — Key figures — 10-K (0001665988-26-000011) |url=https://www.sec.gov/Archives/edgar/data/1665988/000166598826000011/bvs-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-05}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.